Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737230 | 0.72 | — | — | |
| SCHEMBL293794 | 0.71 | ALOX15 (0.45) | GAAMAPT | |
| SCHEMBL20641606 | 0.70 | — | — | |
| SCHEMBL29844361 | 0.70 | — | — | |
| SCHEMBL549069 | 0.70 | — | — | |
| SCHEMBL2879383 | 0.69 | CHRNB2 (0.38) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL3933344 | 0.69 | CHRNB2 (0.38) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| Hydrochloric Acid SCHEMBL4461424 | 0.68 | CHRNB2 (0.55) | CHRNB2CHRNA4SIGMAR1CHRNA7GAA | |
| SCHEMBL987978 | 0.67 | SIGMAR1 (0.54) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL29597435 | 0.67 | SIGMAR1 (0.54) | CHRNB2CHRNA4SIGMAR1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3536692-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3173413-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9796725-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3173413-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9663525-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9593121-B2 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20130217682-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS ,INC (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2416660-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2417115-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010118159-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118155-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | UBA1, UBXN1, UBE2E1 | CHRNB2 4340/4885CHRNA4 4732/4885SIGMAR1 4286/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CHRNB2 2172/4885CHRNA4 1052/4885SIGMAR1 2114/4885 |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CES1 | CHRNB2 1077/4885CHRNA4 927/4885SIGMAR1 799/4885 |
| US-20130217682-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHRNB2 4340/4885CHRNA4 4732/4885SIGMAR1 4286/4885 |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | CHRNB2 1394/4885CHRNA4 1241/4885SIGMAR1 744/4885 |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHRNB2 4340/4885CHRNA4 4732/4885SIGMAR1 4286/4885 |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHRNB2 4340/4885CHRNA4 4732/4885SIGMAR1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.